Oncology · Medical Literature
[The role of indole-3-carbinol and epigallocatechin-3-gallate in maintaining men's health (a systematic literature review)].
Abstract
Benign prostatic hyperplasia (BPH) is a condition that impairs the quality of life and occurs with high frequency in older men. Prostate cancer is one of the most common malignancies in men, characterized by high mortality rates. The aim of the study was to systematize data on the physiological effects and safety profile of the supplement Indigal® containing indole-3-carbinol (I3C) and epigallocatechin-3- gallate (EGCG) to confirm their positive impact on men's health and safety. A search for studies on the clinical effect of I3C, its metabolite diindolylmethane (DIM), green tea catechins (GTC), including EGCG, and their combinations was conducted in the database PubMed, Cochrane Library, ClinicalTrials. gov, WHO ICTRP and eLibrary. The final analysis included 31 publications. The review presents current data on the role of I3C and GTC in maintaining men's health. I3C promotes normal hormonal balance, exhibits antiproliferative and antiandrogenic activity, and improves urodynamics and microcirculation in the prostate gland. GTC have demonstrated a chemopreventive effect regarding the risk of prostate cancer, improved regulation of carbohydrate and lipid metabolism, enhanced energy metabolism, and a beneficial impact on vascular health and cellular vital processes. The supplement Indigal® helps reduce the severity of BPH symptoms, improves urodynamic parameters, normalizes the hormonal profile, and exhibits antiproliferative activity along with beneficial effects on microcirculation. Thus, the supplement can reduce the severity of prostatic intraepithelial neoplasia (PIN) and BPH, improves metabolic processes, increases the body's adaptive capacity, and provides protection at the cellular level. The administration of the complex can be recommended as a dietary supplement, a source of I3C and EGCG, for the support of men's health.
Clinical relevance
Does supplementation with indole-3-carbinol (I3C) and epigallocatechin-3-gallate (EGCG), as formulated in the proprietary supplement Indigal®, exert beneficial and safe physiological effects relevant to benign prostatic hyperplasia and prostate cancer risk in men? __SNAPSHOT__ {"studyDesign":"Systematic literature review (narrative synthesis; no meta-analysis reported)","setting":"Not reported (multi-database literature search: PubMed, Cochrane Library, ClinicalTrials.gov, WHO ICTRP, eLibrary)","sampleSize":"31 publications included in final analysis; individual study sample sizes not reported in the abstract","population":"Men with or at risk for benign prostatic hyperplasia (BPH) and/or prostate cancer; broader metabolic outcomes also addressed","intervention":"I3C, its metabolite diindolylmethane (DIM), green tea catechins (GTC) including EGCG, and their combinations — as represented by the proprietary supplement Indigal®","comparator":"Not applicable (systematic review; comparators within individual included studies not specified in the abstract)","primaryOutcome":"Physiological effects and safety profile of I3C and EGCG on men's health, specifically hormonal balance, antiproliferative and antiandrogenic activity, urodynamics, microcirculation, prostate cancer chemoprevention, and carbohydrate/lipid metabolism regulation","followUp":"Not reported (varies across included primary studies)","fundingSource":"Not reported; notable that the review is explicitly framed around a named proprietary supplement (Indigal®), which raises potential for commercial sponsorship bias"}
Key findings
Based solely on the available abstract, the review synthesized data from 31 publications and reported the following qualitative findings for the two active compound classes: (1) I3C — described as promoting normal hormonal balance, exhibiting antiproliferative and antiandrogenic activity, and improving urodynamics and microcirculation in the prostate gland. (2) Green tea catechins (GTC), principally EGCG — described as demonstrating a chemopreventive effect with respect to prostate cancer risk, and improving regulation of carbohydrate and lipid metabolism; the abstract appears truncated before the full list of GTC effects. No quantitative effect sizes, odds ratios, hazard ratios, confidence intervals, p-values, or NNT/NNH are reported in the abstract. No data on adverse events specific to the included studies are presented in the abstract. All numerical outcomes are 'not reported' in the source material available for this summary.
Practice implications
This review establishes a mechanistically plausible biological rationale for I3C, DIM, and EGCG in prostate health, consistent with published preclinical and epidemiological literature showing antiproliferative, antiandrogenic, and chemopreventive signals for these compounds. However, several critical limitations sharply constrain clinical applicability. First, only an abstract is available for review; full methodology, risk-of-bias assessment, and quantitative synthesis cannot be evaluated. Second, the review is organized explicitly around a proprietary supplement (Indigal®), introducing a framing that may overweight positive findings and underweight null or adverse results — a well-recognized source of bias in supplement-industry-adjacent literature. Third, broader evidence from independent sources consistently demonstrates that human clinical trial data for I3C and EGCG remain limited: I3C has not been proven to prevent cancer in humans, and epidemiological studies on EGCG's anticancer effects have produced conflicting results. Fourth, animal model data raise a context-dependent concern: the timing of I3C exposure can determine whether it inhibits or promotes tumor development, a nuance that a commercially oriented review may not adequately address. Fifth, EGCG's bioavailability is substantially reduced by gut microbial metabolism, limiting translation of in vitro findings. The findings as presented apply most plausibly to older men with BPH or elevated prostate cancer risk, but the review does not specify which patient subgroups benefit most or least. Practice should not change on the basis of this review alone; independent, adequately powered RCTs with patient-centered endpoints are needed before clinical recommendation of these supplements. __LIMITATIONS__ Only an abstract is available; full methodology, search strategy, inclusion/exclusion criteria, and risk-of-bias assessment cannot be verified.,The review is explicitly framed around a named proprietary supplement (Indigal®), raising strong concern for commercial framing bias and selective citation of favorable evidence.,No quantitative pooling or meta-analysis reported; the narrative synthesis cannot be evaluated for heterogeneity or statistical rigor.,The 31-publication corpus is small for a systematic review and the abstract provides no detail on study designs, individual study quality, or the proportion of preclinical versus clinical evidence included.,I3C is chemically unstable in the gastric environment and is rapidly converted to DIM; conflating I3C and DIM effects without pharmacokinetic clarity reduces mechanistic precision.,EGCG has recognized bioavailability limitations due to gut microbial degradation and first-pass metabolism, limiting translation of preclinical findings.,Animal studies demonstrate context-dependent, bidirectional (inhibitory and promoting) tumor effects of I3C, which may not be adequately represented in a commercially oriented review.,Generalizability is uncertain: age, baseline hormonal status, dietary background, comedications (particularly CYP1A2 substrates), and cancer stage of included populations are not reported.,Potential drug interactions (I3C/DIM as CYP enzyme inducers affecting multiple drug classes) and safety signals are not addressed in the abstract.,Publication language bias: inclusion of eLibrary suggests Russian-language literature was searched, which may introduce regional reporting bias. __BOTTOM_LINE_CATEGORY__ not_ready_for_clinical_application __BOTTOM_LINE__ This systematic review reports that I3C, DIM, and EGCG exert antiproliferative, antiandrogenic, and potentially chemopreventive effects relevant to BPH and prostate cancer, but the evidence base remains largely preclinical and the review carries significant commercial framing risk due to its explicit focus on a proprietary supplement. No quantitative effect estimates are available from the abstract, and independent clinical trial data for these compounds in men remain limited and partially conflicting. Clinicians should not recommend Indigal® or similar I3C/EGCG supplements for prostate cancer chemoprevention or BPH management outside of a research context pending adequately powered, independently conducted RCTs.